|
Feb 15
|
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
|
|
Feb 14
|
BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
|
|
Feb 13
|
BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
|
|
Jan 8
|
BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023
|
|
Jan 3
|
BIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARD
|
|
Dec 14
|
BIOLASE RECEIVES TOP WORKPLACES 2023 AWARD
|
|
Dec 12
|
BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser Trial
|
|
Dec 6
|
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Nov 8
|
Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol
|
|
Nov 7
|
BIOLASE TO REPORT THIRD QUARTER 2023 RESULTS ON NOVEMBER 9, 2023
|
|
Oct 18
|
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
|
|
Aug 11
|
Q2 2023 BIOLASE Inc Earnings Call
|
|
Aug 10
|
BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR
|
|
May 24
|
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants
|